| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 138 | 2025 | 502 | 14.940 |
Why?
|
| Herpes Simplex | 124 | 2025 | 203 | 12.560 |
Why?
|
| Simplexvirus | 83 | 2022 | 152 | 7.690 |
Why?
|
| Herpes Zoster | 55 | 2014 | 79 | 5.830 |
Why?
|
| Acyclovir | 75 | 2025 | 110 | 5.800 |
Why?
|
| Herpes Genitalis | 33 | 2022 | 41 | 4.670 |
Why?
|
| Herpesvirus 1, Human | 32 | 2022 | 245 | 4.120 |
Why?
|
| Herpesvirus 2, Human | 24 | 2024 | 45 | 3.980 |
Why?
|
| Influenza, Human | 21 | 2016 | 346 | 3.520 |
Why?
|
| Cytomegalovirus Infections | 43 | 2019 | 155 | 3.390 |
Why?
|
| Pregnancy Complications, Infectious | 29 | 2025 | 125 | 2.950 |
Why?
|
| Encephalitis | 54 | 2015 | 99 | 2.480 |
Why?
|
| Infant, Newborn, Diseases | 21 | 2019 | 116 | 2.230 |
Why?
|
| Oseltamivir | 11 | 2016 | 20 | 2.210 |
Why?
|
| Valine | 13 | 2025 | 62 | 2.050 |
Why?
|
| Herpesviridae Infections | 31 | 2009 | 46 | 2.040 |
Why?
|
| Vidarabine | 53 | 2005 | 145 | 2.040 |
Why?
|
| Virus Shedding | 10 | 2022 | 27 | 2.000 |
Why?
|
| Virus Diseases | 17 | 2017 | 101 | 1.950 |
Why?
|
| Chickenpox | 25 | 2012 | 37 | 1.950 |
Why?
|
| Encephalitis, Herpes Simplex | 9 | 2015 | 16 | 1.870 |
Why?
|
| Infant, Newborn | 89 | 2025 | 2571 | 1.730 |
Why?
|
| Humans | 362 | 2025 | 94647 | 1.510 |
Why?
|
| Ganciclovir | 18 | 2019 | 52 | 1.500 |
Why?
|
| Glioma | 15 | 2014 | 310 | 1.370 |
Why?
|
| 2-Aminopurine | 10 | 2011 | 11 | 1.330 |
Why?
|
| Virus Replication | 33 | 2020 | 324 | 1.310 |
Why?
|
| Drug Resistance, Viral | 11 | 2014 | 48 | 1.310 |
Why?
|
| Interleukin-12 | 8 | 2014 | 116 | 1.230 |
Why?
|
| Drug Discovery | 4 | 2016 | 115 | 1.220 |
Why?
|
| Oncolytic Virotherapy | 7 | 2020 | 43 | 1.130 |
Why?
|
| Disease Outbreaks | 6 | 2008 | 156 | 1.110 |
Why?
|
| Clinical Trials as Topic | 44 | 2019 | 1167 | 1.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 8 | 2024 | 45 | 1.100 |
Why?
|
| DNA, Viral | 21 | 2011 | 273 | 0.980 |
Why?
|
| Herpesvirus 3, Human | 18 | 2011 | 39 | 0.960 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2016 | 924 | 0.940 |
Why?
|
| Genetic Vectors | 10 | 2019 | 448 | 0.880 |
Why?
|
| Herpes Zoster Vaccine | 4 | 2014 | 10 | 0.860 |
Why?
|
| Infant | 48 | 2025 | 3309 | 0.850 |
Why?
|
| Genetic Therapy | 14 | 2019 | 383 | 0.850 |
Why?
|
| Brain Neoplasms | 13 | 2019 | 832 | 0.840 |
Why?
|
| Neuralgia, Postherpetic | 5 | 2010 | 5 | 0.840 |
Why?
|
| Antibodies, Viral | 21 | 2019 | 306 | 0.800 |
Why?
|
| AIDS-Related Opportunistic Infections | 6 | 2012 | 33 | 0.790 |
Why?
|
| Herpesvirus 6, Human | 6 | 2009 | 21 | 0.780 |
Why?
|
| Virus Activation | 7 | 2013 | 42 | 0.760 |
Why?
|
| Female | 139 | 2025 | 49310 | 0.760 |
Why?
|
| Fibromyalgia | 1 | 2022 | 15 | 0.750 |
Why?
|
| Influenza A virus | 4 | 2014 | 173 | 0.750 |
Why?
|
| Helicobacter Infections | 1 | 2022 | 37 | 0.730 |
Why?
|
| Helicobacter pylori | 1 | 2022 | 38 | 0.730 |
Why?
|
| Gastritis | 1 | 2022 | 38 | 0.730 |
Why?
|
| Child | 52 | 2020 | 7485 | 0.700 |
Why?
|
| Pain Measurement | 4 | 2008 | 371 | 0.680 |
Why?
|
| Genetic Engineering | 12 | 2013 | 117 | 0.680 |
Why?
|
| Roseolovirus Infections | 2 | 2014 | 9 | 0.680 |
Why?
|
| Gastrointestinal Diseases | 1 | 2022 | 155 | 0.670 |
Why?
|
| Disease Models, Animal | 13 | 2013 | 2501 | 0.670 |
Why?
|
| Encephalitis, Viral | 6 | 2019 | 7 | 0.650 |
Why?
|
| Polymerase Chain Reaction | 17 | 2012 | 928 | 0.650 |
Why?
|
| Acquired Immunodeficiency Syndrome | 9 | 2007 | 79 | 0.650 |
Why?
|
| Cytomegalovirus | 18 | 2012 | 89 | 0.650 |
Why?
|
| Viral Vaccines | 10 | 2002 | 45 | 0.630 |
Why?
|
| Central Nervous System Viral Diseases | 4 | 2019 | 4 | 0.630 |
Why?
|
| Recurrence | 27 | 2016 | 1200 | 0.620 |
Why?
|
| Administration, Oral | 16 | 2025 | 682 | 0.620 |
Why?
|
| Pain | 9 | 2002 | 416 | 0.600 |
Why?
|
| Viruses | 3 | 2016 | 75 | 0.600 |
Why?
|
| Organophosphonates | 6 | 1998 | 53 | 0.590 |
Why?
|
| Herpes Labialis | 7 | 2011 | 9 | 0.580 |
Why?
|
| Male | 110 | 2025 | 45142 | 0.570 |
Why?
|
| Virus Latency | 4 | 2013 | 34 | 0.570 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2010 | 108 | 0.570 |
Why?
|
| Meningitis, Viral | 3 | 2006 | 7 | 0.560 |
Why?
|
| HIV Infections | 13 | 2010 | 946 | 0.560 |
Why?
|
| Adult | 90 | 2019 | 28308 | 0.560 |
Why?
|
| Zika Virus | 1 | 2017 | 19 | 0.550 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 18 | 0.550 |
Why?
|
| Central Nervous System Diseases | 10 | 2011 | 50 | 0.540 |
Why?
|
| Animals | 65 | 2018 | 28587 | 0.540 |
Why?
|
| Enterovirus Infections | 6 | 2015 | 30 | 0.530 |
Why?
|
| Health Planning | 2 | 2006 | 18 | 0.510 |
Why?
|
| Pregnancy | 31 | 2024 | 3204 | 0.510 |
Why?
|
| Child, Preschool | 28 | 2020 | 3904 | 0.490 |
Why?
|
| Ribavirin | 3 | 2011 | 40 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 13 | 2009 | 1419 | 0.470 |
Why?
|
| Viral Load | 10 | 2015 | 159 | 0.470 |
Why?
|
| Immunocompromised Host | 8 | 2014 | 147 | 0.470 |
Why?
|
| Neuraminidase | 2 | 2013 | 47 | 0.460 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 3 | 2010 | 64 | 0.450 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 186 | 0.450 |
Why?
|
| Guanidines | 1 | 2014 | 32 | 0.450 |
Why?
|
| Treatment Outcome | 23 | 2019 | 8980 | 0.450 |
Why?
|
| Cyclopentanes | 1 | 2014 | 28 | 0.450 |
Why?
|
| Herpes Simplex Virus Vaccines | 3 | 2018 | 5 | 0.440 |
Why?
|
| Viral Envelope Proteins | 13 | 1998 | 94 | 0.420 |
Why?
|
| Arabinofuranosyluracil | 4 | 1998 | 6 | 0.420 |
Why?
|
| Adolescent | 41 | 2020 | 9752 | 0.420 |
Why?
|
| Disease Management | 2 | 2018 | 352 | 0.420 |
Why?
|
| Prednisone | 5 | 1999 | 256 | 0.420 |
Why?
|
| Influenza Vaccines | 4 | 2008 | 155 | 0.410 |
Why?
|
| Oxadiazoles | 3 | 2015 | 39 | 0.410 |
Why?
|
| Viral Proteins | 15 | 2024 | 287 | 0.410 |
Why?
|
| Thiazoles | 1 | 2014 | 130 | 0.400 |
Why?
|
| Hepatitis B | 5 | 2017 | 79 | 0.400 |
Why?
|
| Glioblastoma | 2 | 2013 | 280 | 0.400 |
Why?
|
| Double-Blind Method | 27 | 2015 | 1776 | 0.390 |
Why?
|
| Neuralgia | 5 | 2002 | 33 | 0.390 |
Why?
|
| Vaccination | 5 | 2006 | 293 | 0.390 |
Why?
|
| Chickenpox Vaccine | 3 | 2009 | 7 | 0.380 |
Why?
|
| Encephalitis, California | 1 | 2011 | 2 | 0.370 |
Why?
|
| Immunotherapy | 5 | 2019 | 747 | 0.360 |
Why?
|
| Pyridines | 1 | 2014 | 317 | 0.360 |
Why?
|
| Respiratory Syncytial Viruses | 4 | 2015 | 17 | 0.360 |
Why?
|
| Middle Aged | 56 | 2019 | 27900 | 0.350 |
Why?
|
| Academies and Institutes | 1 | 2011 | 34 | 0.350 |
Why?
|
| Guanine | 8 | 1999 | 207 | 0.340 |
Why?
|
| Anti-Infective Agents | 7 | 2008 | 92 | 0.330 |
Why?
|
| Time Factors | 29 | 2015 | 5530 | 0.330 |
Why?
|
| West Nile Fever | 3 | 2019 | 22 | 0.330 |
Why?
|
| Ferrets | 1 | 2010 | 48 | 0.330 |
Why?
|
| Universities | 1 | 2011 | 152 | 0.320 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2010 | 49 | 0.320 |
Why?
|
| United States | 21 | 2014 | 7642 | 0.320 |
Why?
|
| Conflict of Interest | 2 | 2010 | 76 | 0.310 |
Why?
|
| Aged | 35 | 2019 | 20601 | 0.310 |
Why?
|
| Hearing Loss, Sensorineural | 3 | 2019 | 51 | 0.310 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2001 | 94 | 0.310 |
Why?
|
| Hearing Loss, Central | 1 | 2009 | 3 | 0.310 |
Why?
|
| Disclosure | 1 | 2010 | 111 | 0.300 |
Why?
|
| Vaccines, Synthetic | 4 | 2005 | 58 | 0.290 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 60 | 0.290 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2015 | 27 | 0.290 |
Why?
|
| Keratitis, Dendritic | 9 | 1988 | 13 | 0.290 |
Why?
|
| Arenavirus | 1 | 2008 | 1 | 0.280 |
Why?
|
| Arenaviridae Infections | 1 | 2008 | 4 | 0.280 |
Why?
|
| Oncolytic Viruses | 4 | 2019 | 24 | 0.280 |
Why?
|
| Antigens, Viral | 12 | 1996 | 133 | 0.280 |
Why?
|
| Brain | 23 | 2012 | 2415 | 0.270 |
Why?
|
| HIV Seropositivity | 3 | 2012 | 52 | 0.260 |
Why?
|
| Government Programs | 1 | 2006 | 9 | 0.260 |
Why?
|
| Meningitis, Bacterial | 3 | 2004 | 14 | 0.260 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 35 | 0.260 |
Why?
|
| Neonatal Screening | 1 | 2008 | 66 | 0.260 |
Why?
|
| Genes, Viral | 6 | 2013 | 108 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2014 | 153 | 0.260 |
Why?
|
| Incidence | 8 | 2009 | 1691 | 0.260 |
Why?
|
| Drug Resistance, Microbial | 9 | 1996 | 75 | 0.260 |
Why?
|
| Headache | 2 | 2006 | 81 | 0.250 |
Why?
|
| Immunization, Passive | 4 | 1994 | 72 | 0.250 |
Why?
|
| HIV-1 | 8 | 2012 | 166 | 0.250 |
Why?
|
| Clinical Trials Data Monitoring Committees | 2 | 2004 | 5 | 0.240 |
Why?
|
| Interferon Type I | 7 | 1999 | 205 | 0.240 |
Why?
|
| Mice | 28 | 2014 | 12428 | 0.240 |
Why?
|
| Seasons | 5 | 2014 | 242 | 0.240 |
Why?
|
| Drug Administration Schedule | 11 | 2015 | 868 | 0.240 |
Why?
|
| Disease Transmission, Infectious | 3 | 2016 | 59 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 713 | 0.230 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 113 | 0.230 |
Why?
|
| Prevalence | 6 | 2022 | 1330 | 0.230 |
Why?
|
| Proportional Hazards Models | 4 | 2002 | 889 | 0.230 |
Why?
|
| Condylomata Acuminata | 4 | 1988 | 15 | 0.230 |
Why?
|
| Central Nervous System | 6 | 2010 | 152 | 0.220 |
Why?
|
| Diphosphates | 2 | 2008 | 18 | 0.220 |
Why?
|
| Organophosphorus Compounds | 5 | 1998 | 53 | 0.220 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 901 | 0.220 |
Why?
|
| Hepatitis B virus | 1 | 2004 | 47 | 0.220 |
Why?
|
| HIV | 1 | 2004 | 48 | 0.220 |
Why?
|
| Hepacivirus | 2 | 2005 | 137 | 0.220 |
Why?
|
| Cytosine | 5 | 1998 | 134 | 0.210 |
Why?
|
| Smallpox | 2 | 2003 | 6 | 0.210 |
Why?
|
| Analgesics | 3 | 2010 | 125 | 0.210 |
Why?
|
| Hepatitis C | 2 | 2004 | 182 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2007 | 355 | 0.200 |
Why?
|
| Variola virus | 1 | 2003 | 1 | 0.200 |
Why?
|
| Biological Warfare | 1 | 2003 | 6 | 0.200 |
Why?
|
| United States Food and Drug Administration | 1 | 2004 | 141 | 0.200 |
Why?
|
| Bioterrorism | 1 | 2003 | 18 | 0.200 |
Why?
|
| Smallpox Vaccine | 1 | 2003 | 13 | 0.200 |
Why?
|
| Drug Evaluation | 14 | 1996 | 136 | 0.200 |
Why?
|
| Risk Factors | 11 | 2012 | 5861 | 0.190 |
Why?
|
| Mice, SCID | 5 | 2012 | 278 | 0.190 |
Why?
|
| Cross Infection | 4 | 2010 | 156 | 0.190 |
Why?
|
| Cytomegalovirus Retinitis | 2 | 1999 | 8 | 0.190 |
Why?
|
| Anti-HIV Agents | 4 | 1999 | 196 | 0.190 |
Why?
|
| Glycoproteins | 7 | 1988 | 233 | 0.190 |
Why?
|
| Research Design | 9 | 1997 | 614 | 0.190 |
Why?
|
| Enterovirus | 3 | 2015 | 19 | 0.190 |
Why?
|
| Age Factors | 11 | 2014 | 1945 | 0.190 |
Why?
|
| West Nile virus | 2 | 2019 | 17 | 0.190 |
Why?
|
| Respiratory Tract Infections | 5 | 2006 | 113 | 0.180 |
Why?
|
| Cell Line | 11 | 2019 | 2531 | 0.180 |
Why?
|
| Immunocompetence | 3 | 2009 | 27 | 0.180 |
Why?
|
| Sulfonamides | 2 | 2014 | 334 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 1078 | 0.180 |
Why?
|
| Killer Cells, Natural | 6 | 1990 | 282 | 0.180 |
Why?
|
| Nervous System Diseases | 5 | 2014 | 168 | 0.180 |
Why?
|
| Acetamides | 1 | 2001 | 27 | 0.170 |
Why?
|
| Glucocorticoids | 2 | 2009 | 371 | 0.170 |
Why?
|
| Likelihood Functions | 1 | 2001 | 254 | 0.170 |
Why?
|
| Vaccines, Attenuated | 5 | 2005 | 57 | 0.170 |
Why?
|
| RNA, Viral | 3 | 2013 | 305 | 0.170 |
Why?
|
| Biopsy | 14 | 1991 | 1213 | 0.160 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 44 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 1991 | 48 | 0.160 |
Why?
|
| Immune Tolerance | 6 | 1990 | 379 | 0.160 |
Why?
|
| Temporal Lobe | 2 | 2015 | 192 | 0.160 |
Why?
|
| Foscarnet | 2 | 1998 | 11 | 0.160 |
Why?
|
| Pneumonia, Viral | 7 | 2006 | 339 | 0.160 |
Why?
|
| Data Interpretation, Statistical | 1 | 2001 | 308 | 0.160 |
Why?
|
| Immunoglobulin G | 3 | 2019 | 468 | 0.160 |
Why?
|
| Injections, Intravenous | 9 | 2009 | 238 | 0.160 |
Why?
|
| Intussusception | 1 | 1999 | 16 | 0.160 |
Why?
|
| Rotavirus Infections | 1 | 1999 | 12 | 0.160 |
Why?
|
| Genetic Variation | 4 | 2019 | 1408 | 0.160 |
Why?
|
| Therapies, Investigational | 1 | 2019 | 18 | 0.160 |
Why?
|
| Cooperative Behavior | 2 | 2011 | 189 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 66 | 0.150 |
Why?
|
| Rubella | 2 | 2017 | 3 | 0.150 |
Why?
|
| Herpesvirus 7, Human | 1 | 1998 | 3 | 0.150 |
Why?
|
| Eye Infections, Viral | 2 | 1996 | 4 | 0.150 |
Why?
|
| Infusions, Intravenous | 6 | 2011 | 421 | 0.150 |
Why?
|
| Ribonucleosides | 1 | 1998 | 26 | 0.150 |
Why?
|
| Virulence | 4 | 2006 | 279 | 0.150 |
Why?
|
| Survival Analysis | 4 | 2012 | 1530 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2020 | 327 | 0.140 |
Why?
|
| Acute Disease | 4 | 2014 | 864 | 0.140 |
Why?
|
| Gene Editing | 1 | 2018 | 52 | 0.140 |
Why?
|
| Drug Therapy, Combination | 7 | 2015 | 810 | 0.140 |
Why?
|
| Americas | 1 | 2017 | 20 | 0.140 |
Why?
|
| Caribbean Region | 1 | 2017 | 24 | 0.140 |
Why?
|
| Sexual Behavior | 3 | 2012 | 330 | 0.140 |
Why?
|
| Administration, Topical | 5 | 2011 | 97 | 0.140 |
Why?
|
| Fetal Diseases | 4 | 1989 | 81 | 0.140 |
Why?
|
| Influenza in Birds | 2 | 2008 | 31 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1933 | 0.140 |
Why?
|
| Alphaherpesvirinae | 1 | 1997 | 1 | 0.130 |
Why?
|
| Interleukins | 1 | 1998 | 134 | 0.130 |
Why?
|
| Regression Analysis | 6 | 2014 | 597 | 0.130 |
Why?
|
| Multivariate Analysis | 6 | 2015 | 1006 | 0.130 |
Why?
|
| Disease Progression | 5 | 2006 | 1538 | 0.130 |
Why?
|
| Mouth Diseases | 2 | 1996 | 16 | 0.130 |
Why?
|
| Orthomyxoviridae | 2 | 2012 | 41 | 0.130 |
Why?
|
| Alabama | 3 | 2011 | 10 | 0.130 |
Why?
|
| Prospective Studies | 12 | 2014 | 4598 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 640 | 0.130 |
Why?
|
| Models, Statistical | 3 | 2015 | 584 | 0.120 |
Why?
|
| Gestational Age | 4 | 2019 | 337 | 0.120 |
Why?
|
| Skin Diseases, Viral | 1 | 1996 | 3 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2014 | 181 | 0.120 |
Why?
|
| Primary Prevention | 2 | 2006 | 85 | 0.120 |
Why?
|
| Aotidae | 2 | 2014 | 7 | 0.120 |
Why?
|
| Prenatal Care | 2 | 2007 | 83 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 63 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 68 | 0.120 |
Why?
|
| Young Adult | 5 | 2015 | 6868 | 0.120 |
Why?
|
| Gene Expression | 4 | 2012 | 1322 | 0.120 |
Why?
|
| Immediate-Early Proteins | 3 | 1997 | 164 | 0.120 |
Why?
|
| Neonatal Sepsis | 1 | 2015 | 6 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 86 | 0.110 |
Why?
|
| Acids, Carbocyclic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Seizures | 4 | 1998 | 326 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2014 | 22 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2014 | 65 | 0.110 |
Why?
|
| Cells, Cultured | 11 | 2015 | 2942 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2015 | 10040 | 0.110 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2014 | 22 | 0.110 |
Why?
|
| Organ Transplantation | 2 | 2008 | 297 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 16 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2012 | 377 | 0.110 |
Why?
|
| Mouth | 3 | 2005 | 49 | 0.110 |
Why?
|
| Receptors, Virus | 1 | 2014 | 76 | 0.110 |
Why?
|
| Newspapers as Topic | 1 | 2014 | 6 | 0.110 |
Why?
|
| Infusions, Intraventricular | 1 | 2014 | 6 | 0.110 |
Why?
|
| History, 20th Century | 5 | 2004 | 322 | 0.110 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2014 | 18 | 0.110 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2013 | 7 | 0.110 |
Why?
|
| Infertility | 1 | 2014 | 35 | 0.110 |
Why?
|
| Oxazoles | 3 | 2015 | 18 | 0.110 |
Why?
|
| Genome, Viral | 3 | 2019 | 80 | 0.110 |
Why?
|
| Base Sequence | 8 | 1998 | 2342 | 0.110 |
Why?
|
| Eye | 3 | 2005 | 112 | 0.100 |
Why?
|
| Stomatitis, Herpetic | 4 | 1986 | 5 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2015 | 128 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 7099 | 0.100 |
Why?
|
| Child Development | 2 | 2015 | 174 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 178 | 0.100 |
Why?
|
| Severity of Illness Index | 6 | 2014 | 1959 | 0.100 |
Why?
|
| Arabinonucleotides | 2 | 1985 | 3 | 0.100 |
Why?
|
| Vidarabine Phosphate | 2 | 1985 | 5 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2014 | 159 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 1117 | 0.100 |
Why?
|
| Managed Care Programs | 2 | 2007 | 43 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2013 | 25 | 0.100 |
Why?
|
| Interleukin-15 | 1 | 2013 | 76 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 239 | 0.100 |
Why?
|
| Molecular Sequence Data | 8 | 1998 | 3047 | 0.100 |
Why?
|
| Cell Fusion | 3 | 1989 | 39 | 0.100 |
Why?
|
| Clinical Protocols | 5 | 2006 | 159 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2014 | 123 | 0.100 |
Why?
|
| Neutropenia | 2 | 2015 | 218 | 0.100 |
Why?
|
| Vaccines, Inactivated | 3 | 2002 | 30 | 0.100 |
Why?
|
| Kidney Transplantation | 7 | 2012 | 876 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2007 | 154 | 0.100 |
Why?
|
| Interferons | 5 | 1994 | 129 | 0.100 |
Why?
|
| Viral Matrix Proteins | 1 | 2012 | 15 | 0.100 |
Why?
|
| Drug Users | 1 | 2012 | 30 | 0.100 |
Why?
|
| Students, Dental | 1 | 1992 | 4 | 0.090 |
Why?
|
| Vero Cells | 6 | 2006 | 104 | 0.090 |
Why?
|
| Quality of Life | 5 | 2015 | 1794 | 0.090 |
Why?
|
| Anticonvulsants | 2 | 2010 | 130 | 0.090 |
Why?
|
| La Crosse virus | 1 | 2011 | 2 | 0.090 |
Why?
|
| Follow-Up Studies | 13 | 2015 | 3871 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 110 | 0.090 |
Why?
|
| Random Allocation | 8 | 1999 | 330 | 0.090 |
Why?
|
| Prognosis | 7 | 2014 | 3976 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 6 | 2020 | 154 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 99 | 0.090 |
Why?
|
| Prodrugs | 3 | 1999 | 54 | 0.090 |
Why?
|
| Nonprescription Drugs | 1 | 2011 | 18 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 245 | 0.090 |
Why?
|
| Neoplasms | 9 | 2005 | 3205 | 0.090 |
Why?
|
| Global Health | 2 | 2006 | 208 | 0.090 |
Why?
|
| Algorithms | 2 | 2013 | 1980 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2007 | 2030 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2011 | 39 | 0.090 |
Why?
|
| Forecasting | 3 | 1997 | 314 | 0.090 |
Why?
|
| Tunicamycin | 2 | 1990 | 14 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2012 | 266 | 0.090 |
Why?
|
| Cancer Vaccines | 2 | 2005 | 167 | 0.090 |
Why?
|
| Reference Values | 2 | 2003 | 668 | 0.090 |
Why?
|
| Meningoencephalitis | 4 | 1998 | 9 | 0.090 |
Why?
|
| Societies | 1 | 2010 | 16 | 0.090 |
Why?
|
| Rabbits | 7 | 1993 | 646 | 0.090 |
Why?
|
| Diagnosis, Differential | 9 | 2015 | 1608 | 0.080 |
Why?
|
| Genomics | 2 | 2019 | 834 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2010 | 21 | 0.080 |
Why?
|
| Adamantane | 1 | 2010 | 7 | 0.080 |
Why?
|
| Rimantadine | 1 | 2010 | 9 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 9 | 1993 | 327 | 0.080 |
Why?
|
| Transplantation, Heterologous | 4 | 2006 | 378 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 527 | 0.080 |
Why?
|
| Financial Support | 1 | 2010 | 8 | 0.080 |
Why?
|
| Circumcision, Male | 1 | 2010 | 20 | 0.080 |
Why?
|
| Guanosine Triphosphate | 1 | 1990 | 38 | 0.080 |
Why?
|
| Neuroblastoma | 2 | 2006 | 395 | 0.080 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2009 | 6 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1990 | 214 | 0.080 |
Why?
|
| Herpesviridae | 1 | 2009 | 14 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2007 | 1957 | 0.080 |
Why?
|
| Herpes Zoster Oticus | 1 | 2009 | 2 | 0.080 |
Why?
|
| Drug Industry | 1 | 2010 | 58 | 0.080 |
Why?
|
| Infection Control | 1 | 2010 | 132 | 0.080 |
Why?
|
| Trigeminal Nerve | 4 | 1993 | 18 | 0.080 |
Why?
|
| Viremia | 2 | 2004 | 50 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 209 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2001 | 976 | 0.080 |
Why?
|
| Risk | 4 | 2006 | 665 | 0.080 |
Why?
|
| Fever | 5 | 1999 | 131 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2002 | 290 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2007 | 91 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 2 | 1988 | 110 | 0.070 |
Why?
|
| Gene Products, gag | 2 | 2007 | 12 | 0.070 |
Why?
|
| Publishing | 1 | 2010 | 93 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 1988 | 27 | 0.070 |
Why?
|
| History, 19th Century | 3 | 2001 | 59 | 0.070 |
Why?
|
| Genital Neoplasms, Male | 2 | 1988 | 11 | 0.070 |
Why?
|
| Models, Biological | 2 | 2014 | 1801 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2011 | 2438 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2008 | 39 | 0.070 |
Why?
|
| Middle East | 1 | 2008 | 19 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 1988 | 11 | 0.070 |
Why?
|
| Asia | 1 | 2008 | 103 | 0.070 |
Why?
|
| Osteomyelitis | 1 | 1988 | 56 | 0.070 |
Why?
|
| Idoxuridine | 7 | 1985 | 16 | 0.070 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 55 | 0.070 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 7 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 205 | 0.070 |
Why?
|
| DNA Restriction Enzymes | 3 | 1987 | 97 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 1990 | 247 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 21 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 1990 | 455 | 0.070 |
Why?
|
| Sweden | 1 | 2007 | 45 | 0.070 |
Why?
|
| Placebos | 5 | 2004 | 213 | 0.070 |
Why?
|
| Biomarkers | 2 | 2004 | 1895 | 0.070 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 1756 | 0.070 |
Why?
|
| Anesthetics | 1 | 2008 | 56 | 0.070 |
Why?
|
| History, 18th Century | 2 | 2001 | 22 | 0.070 |
Why?
|
| Arabinonucleosides | 2 | 1985 | 39 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 182 | 0.070 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 58 | 0.070 |
Why?
|
| Zanamivir | 1 | 2006 | 2 | 0.070 |
Why?
|
| Poultry | 1 | 2006 | 24 | 0.060 |
Why?
|
| Genital Neoplasms, Female | 2 | 1988 | 114 | 0.060 |
Why?
|
| Medical Records | 1 | 2007 | 124 | 0.060 |
Why?
|
| Leukemia | 2 | 2006 | 326 | 0.060 |
Why?
|
| Cytosine Deaminase | 1 | 2006 | 9 | 0.060 |
Why?
|
| Financial Management | 1 | 2006 | 21 | 0.060 |
Why?
|
| Herpes Zoster Ophthalmicus | 2 | 2002 | 5 | 0.060 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2006 | 73 | 0.060 |
Why?
|
| Homes for the Aged | 1 | 2006 | 27 | 0.060 |
Why?
|
| Genital Diseases, Male | 1 | 2006 | 9 | 0.060 |
Why?
|
| Birds | 1 | 2008 | 172 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 1987 | 180 | 0.060 |
Why?
|
| Neuritis | 2 | 1999 | 8 | 0.060 |
Why?
|
| Viral Interference | 1 | 1985 | 3 | 0.060 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 404 | 0.060 |
Why?
|
| Trigeminal Ganglion | 1 | 2005 | 16 | 0.060 |
Why?
|
| Parvoviridae Infections | 1 | 1985 | 6 | 0.060 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1998 | 23 | 0.060 |
Why?
|
| Cognition | 1 | 1990 | 615 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2014 | 338 | 0.060 |
Why?
|
| Mass Screening | 2 | 2012 | 707 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 1987 | 468 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2006 | 114 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 47 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2011 | 880 | 0.060 |
Why?
|
| Genetic Markers | 1 | 1986 | 477 | 0.060 |
Why?
|
| Infant, Premature | 3 | 2010 | 307 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 1984 | 185 | 0.060 |
Why?
|
| Hantavirus Pulmonary Syndrome | 1 | 2004 | 1 | 0.060 |
Why?
|
| Retinitis | 2 | 1998 | 3 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 237 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2005 | 141 | 0.060 |
Why?
|
| Aspartate Aminotransferases | 3 | 2001 | 75 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2005 | 97 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 72 | 0.050 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2004 | 52 | 0.050 |
Why?
|
| Computational Biology | 1 | 2008 | 572 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2004 | 65 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 1984 | 4 | 0.050 |
Why?
|
| Tropism | 1 | 2024 | 4 | 0.050 |
Why?
|
| Recombinant Proteins | 6 | 1999 | 1024 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 2755 | 0.050 |
Why?
|
| Skin Diseases, Infectious | 4 | 1992 | 12 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 74 | 0.050 |
Why?
|
| Secondary Prevention | 3 | 2011 | 174 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3600 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 1985 | 216 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2004 | 70 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 657 | 0.050 |
Why?
|
| Consciousness | 3 | 1991 | 31 | 0.050 |
Why?
|
| Chlamydia Infections | 3 | 2012 | 32 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 6 | 2006 | 1057 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 3 | 1998 | 28 | 0.050 |
Why?
|
| Kidney | 5 | 1992 | 1154 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2012 | 472 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2004 | 91 | 0.050 |
Why?
|
| Safety | 2 | 2001 | 146 | 0.050 |
Why?
|
| Immunity, Cellular | 5 | 1992 | 186 | 0.050 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2006 | 6 | 0.050 |
Why?
|
| Convalescence | 2 | 2001 | 12 | 0.050 |
Why?
|
| Communication | 1 | 2006 | 470 | 0.050 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2009 | 24 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 511 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2004 | 165 | 0.050 |
Why?
|
| Purine Nucleosides | 4 | 1976 | 7 | 0.050 |
Why?
|
| Leukocyte Count | 4 | 1997 | 226 | 0.050 |
Why?
|
| Immunoblotting | 4 | 1991 | 280 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2024 | 218 | 0.050 |
Why?
|
| Aging | 2 | 2007 | 752 | 0.050 |
Why?
|
| Kinetics | 6 | 1983 | 1560 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1988 | 592 | 0.050 |
Why?
|
| Mothers | 1 | 2024 | 154 | 0.050 |
Why?
|
| Drug Implants | 2 | 1999 | 38 | 0.050 |
Why?
|
| Bacteria | 1 | 2006 | 507 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 2 | 2005 | 40 | 0.050 |
Why?
|
| Vaccines, Subunit | 1 | 2002 | 55 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 1997 | 492 | 0.050 |
Why?
|
| Arboviruses | 1 | 2002 | 2 | 0.050 |
Why?
|
| Splenomegaly | 2 | 2003 | 29 | 0.050 |
Why?
|
| Hepatomegaly | 2 | 2003 | 16 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2002 | 26 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2001 | 17 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 825 | 0.050 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2001 | 5 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 261 | 0.050 |
Why?
|
| Mutation | 3 | 2024 | 4326 | 0.050 |
Why?
|
| T-Lymphocytes | 6 | 1989 | 1307 | 0.050 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 1981 | 49 | 0.040 |
Why?
|
| History, Medieval | 1 | 2001 | 13 | 0.040 |
Why?
|
| Skin | 3 | 1996 | 603 | 0.040 |
Why?
|
| Chorioretinitis | 2 | 1993 | 9 | 0.040 |
Why?
|
| Evidence-Based Medicine | 3 | 2008 | 449 | 0.040 |
Why?
|
| History, Ancient | 1 | 2001 | 78 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2005 | 1823 | 0.040 |
Why?
|
| Bias | 1 | 2001 | 138 | 0.040 |
Why?
|
| Encephalomyelitis, Equine | 1 | 1980 | 1 | 0.040 |
Why?
|
| Cough | 1 | 2001 | 57 | 0.040 |
Why?
|
| Neutralization Tests | 4 | 1991 | 71 | 0.040 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 2 | 2015 | 19 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 1783 | 0.040 |
Why?
|
| Rats | 1 | 2006 | 4108 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 1992 | 175 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 1992 | 170 | 0.040 |
Why?
|
| Capsid | 3 | 1992 | 25 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 3049 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 937 | 0.040 |
Why?
|
| Viral Core Proteins | 3 | 1991 | 28 | 0.040 |
Why?
|
| Rotavirus | 1 | 1999 | 11 | 0.040 |
Why?
|
| Body Weight | 2 | 2014 | 458 | 0.040 |
Why?
|
| North America | 2 | 2014 | 193 | 0.040 |
Why?
|
| Microscopy, Electron | 4 | 1996 | 509 | 0.040 |
Why?
|
| Arbovirus Infections | 1 | 1999 | 2 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 1999 | 23 | 0.040 |
Why?
|
| Biological Availability | 2 | 2014 | 90 | 0.040 |
Why?
|
| Phenotype | 4 | 2019 | 2543 | 0.040 |
Why?
|
| Rabies | 1 | 1999 | 7 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 909 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 3452 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1998 | 211 | 0.040 |
Why?
|
| Ganglia | 3 | 1990 | 15 | 0.040 |
Why?
|
| Biotransformation | 2 | 2014 | 49 | 0.040 |
Why?
|
| Retroviridae Infections | 1 | 1999 | 46 | 0.040 |
Why?
|
| Medical History Taking | 2 | 2005 | 86 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2019 | 128 | 0.040 |
Why?
|
| Vinyl Chloride | 1 | 1998 | 1 | 0.040 |
Why?
|
| Radioimmunoassay | 3 | 1994 | 151 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2005 | 1199 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 1989 | 148 | 0.030 |
Why?
|
| Pneumonia | 3 | 1987 | 196 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 1999 | 215 | 0.030 |
Why?
|
| Carcinogens | 1 | 1998 | 112 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 1995 | 23 | 0.030 |
Why?
|
| Urine | 2 | 1997 | 96 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1998 | 134 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 1997 | 73 | 0.030 |
Why?
|
| Respirovirus Infections | 2 | 1987 | 10 | 0.030 |
Why?
|
| Platelet Count | 1 | 1997 | 95 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1998 | 180 | 0.030 |
Why?
|
| Opportunistic Infections | 2 | 2008 | 60 | 0.030 |
Why?
|
| Bilirubin | 1 | 1997 | 134 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1998 | 166 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 1998 | 89 | 0.030 |
Why?
|
| Cost of Illness | 1 | 1997 | 159 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2014 | 1148 | 0.030 |
Why?
|
| Occupational Diseases | 2 | 1998 | 56 | 0.030 |
Why?
|
| Probability | 2 | 2003 | 362 | 0.030 |
Why?
|
| Immunosorbent Techniques | 2 | 1986 | 13 | 0.030 |
Why?
|
| Astrocytes | 1 | 1997 | 148 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 1999 | 500 | 0.030 |
Why?
|
| Recombination, Genetic | 3 | 2011 | 444 | 0.030 |
Why?
|
| Retroviridae | 1 | 1996 | 76 | 0.030 |
Why?
|
| International Cooperation | 1 | 1996 | 130 | 0.030 |
Why?
|
| Lymphocyte Activation | 4 | 1989 | 800 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1991 | 694 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1998 | 261 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 1996 | 116 | 0.030 |
Why?
|
| Survival Rate | 2 | 1999 | 1963 | 0.030 |
Why?
|
| Professional Staff Committees | 1 | 1995 | 7 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 2 | 1987 | 122 | 0.030 |
Why?
|
| Hospitals, Special | 1 | 1975 | 8 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1996 | 217 | 0.030 |
Why?
|
| Myelitis, Transverse | 1 | 1995 | 10 | 0.030 |
Why?
|
| Morphogenesis | 2 | 1989 | 208 | 0.030 |
Why?
|
| Injections | 2 | 2013 | 123 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1998 | 287 | 0.030 |
Why?
|
| Antigens, Surface | 4 | 1990 | 105 | 0.030 |
Why?
|
| Adenoviridae | 1 | 1996 | 342 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 311 | 0.030 |
Why?
|
| Oropharynx | 1 | 2015 | 15 | 0.030 |
Why?
|
| Half-Life | 3 | 2005 | 98 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1996 | 236 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1996 | 360 | 0.030 |
Why?
|
| Advisory Committees | 1 | 1995 | 94 | 0.030 |
Why?
|
| Audiometry | 1 | 2015 | 13 | 0.030 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2015 | 5 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1995 | 1008 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 1999 | 583 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2010 | 2825 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 456 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1995 | 135 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2015 | 182 | 0.030 |
Why?
|
| Nectins | 1 | 2014 | 9 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 1987 | 18 | 0.030 |
Why?
|
| California | 1 | 2015 | 159 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 547 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 1998 | 297 | 0.030 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 1986 | 16 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 129 | 0.030 |
Why?
|
| Drug Approval | 1 | 2015 | 67 | 0.030 |
Why?
|
| Carboxylic Acids | 1 | 2014 | 17 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 60 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2014 | 19 | 0.030 |
Why?
|
| Databases, Factual | 1 | 1998 | 987 | 0.030 |
Why?
|
| Rectum | 1 | 2015 | 149 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 1882 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 1996 | 2844 | 0.030 |
Why?
|
| Cell Survival | 1 | 1996 | 1025 | 0.030 |
Why?
|
| Staphylococcal Protein A | 1 | 1994 | 42 | 0.030 |
Why?
|
| Radiography | 2 | 2014 | 810 | 0.030 |
Why?
|
| Mice, Nude | 3 | 2002 | 837 | 0.030 |
Why?
|
| Hepatitis | 2 | 2005 | 35 | 0.030 |
Why?
|
| Keratoconjunctivitis | 2 | 1984 | 5 | 0.030 |
Why?
|
| Benzoxazoles | 1 | 1993 | 4 | 0.030 |
Why?
|
| Mice, Inbred A | 2 | 2006 | 23 | 0.030 |
Why?
|
| Peptides | 2 | 1988 | 670 | 0.030 |
Why?
|
| Orthopedics | 1 | 1975 | 138 | 0.030 |
Why?
|
| Creatinine | 2 | 2003 | 299 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 566 | 0.030 |
Why?
|
| Diabetes Insipidus | 1 | 1993 | 17 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 1988 | 164 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2015 | 125 | 0.030 |
Why?
|
| Basidiomycota | 1 | 1993 | 10 | 0.030 |
Why?
|
| Immunization | 2 | 2007 | 163 | 0.030 |
Why?
|
| Fibroblasts | 4 | 1990 | 784 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2015 | 241 | 0.030 |
Why?
|
| Ganglia, Spinal | 1 | 1993 | 76 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 188 | 0.020 |
Why?
|
| Pyridones | 1 | 1993 | 68 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 433 | 0.020 |
Why?
|
| Meningitis, Cryptococcal | 1 | 1992 | 2 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 1993 | 93 | 0.020 |
Why?
|
| Gonorrhea | 1 | 2012 | 23 | 0.020 |
Why?
|
| Trifluridine | 2 | 1985 | 6 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 3 | 2001 | 81 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2014 | 1132 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 1104 | 0.020 |
Why?
|
| Genital Diseases, Female | 3 | 1985 | 24 | 0.020 |
Why?
|
| Syphilis | 1 | 2012 | 35 | 0.020 |
Why?
|
| Infusions, Parenteral | 2 | 2001 | 51 | 0.020 |
Why?
|
| HLA-DR Antigens | 2 | 1989 | 59 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 1992 | 70 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 1206 | 0.020 |
Why?
|
| Vagina | 1 | 1993 | 179 | 0.020 |
Why?
|
| Virus Cultivation | 2 | 2006 | 18 | 0.020 |
Why?
|
| Macaca | 1 | 1992 | 89 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1992 | 227 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1992 | 172 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 706 | 0.020 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1991 | 32 | 0.020 |
Why?
|
| Viral Plaque Assay | 1 | 1990 | 19 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2155 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2010 | 55 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 1990 | 41 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1990 | 27 | 0.020 |
Why?
|
| Heterosexuality | 1 | 2010 | 21 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2007 | 645 | 0.020 |
Why?
|
| Lung | 2 | 2015 | 1361 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1987 | 43 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Zidovudine | 3 | 1995 | 16 | 0.020 |
Why?
|
| Herpesvirus 8, Human | 1 | 2009 | 11 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 69 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 210 | 0.020 |
Why?
|
| Pyrimethamine | 2 | 1995 | 21 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 877 | 0.020 |
Why?
|
| Inclusion Bodies, Viral | 2 | 1985 | 8 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 1992 | 446 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 308 | 0.020 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1988 | 11 | 0.020 |
Why?
|
| Health Policy | 1 | 2010 | 204 | 0.020 |
Why?
|
| Methisazone | 2 | 1978 | 2 | 0.020 |
Why?
|
| Amantadine | 2 | 1978 | 19 | 0.020 |
Why?
|
| Flucytosine | 1 | 1988 | 11 | 0.020 |
Why?
|
| Amphotericin B | 1 | 1988 | 37 | 0.020 |
Why?
|
| Sacroiliac Joint | 1 | 1988 | 11 | 0.020 |
Why?
|
| Ilium | 1 | 1988 | 23 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 1990 | 532 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 443 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1999 | 1790 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1994 | 273 | 0.020 |
Why?
|
| Pharmacokinetics | 1 | 1987 | 11 | 0.020 |
Why?
|
| Pediatrics | 1 | 2012 | 386 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1990 | 1082 | 0.020 |
Why?
|
| Hepatitis D | 1 | 1987 | 7 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 190 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2007 | 24 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1987 | 26 | 0.020 |
Why?
|
| Aerosols | 1 | 2006 | 48 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1987 | 347 | 0.020 |
Why?
|
| Epithelium | 1 | 1988 | 328 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2006 | 52 | 0.020 |
Why?
|
| Nucleosides | 2 | 1979 | 23 | 0.020 |
Why?
|
| Cytarabine | 2 | 1978 | 222 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 1984 | 300 | 0.020 |
Why?
|
| Sex Factors | 1 | 1990 | 1120 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 107 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2007 | 82 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1987 | 299 | 0.020 |
Why?
|
| Genes | 1 | 1987 | 308 | 0.020 |
Why?
|
| Family Practice | 1 | 2007 | 85 | 0.020 |
Why?
|
| Antineoplastic Agents | 3 | 2005 | 2411 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 134 | 0.020 |
Why?
|
| Myelitis | 1 | 1986 | 2 | 0.020 |
Why?
|
| Hemiplegia | 1 | 1986 | 16 | 0.020 |
Why?
|
| Nuclear Envelope | 1 | 1986 | 39 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 1986 | 8 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2006 | 35 | 0.020 |
Why?
|
| Virion | 1 | 1986 | 60 | 0.020 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1986 | 11 | 0.020 |
Why?
|
| Olfactory Bulb | 1 | 1986 | 41 | 0.020 |
Why?
|
| Cerebellar Ataxia | 1 | 1986 | 24 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1985 | 78 | 0.010 |
Why?
|
| Postoperative Complications | 3 | 1984 | 2514 | 0.010 |
Why?
|
| Graft Survival | 2 | 1979 | 941 | 0.010 |
Why?
|
| Immunity | 1 | 1987 | 153 | 0.010 |
Why?
|
| Phylogeny | 1 | 2011 | 1252 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1985 | 118 | 0.010 |
Why?
|
| Epitopes | 1 | 1986 | 249 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1986 | 117 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2005 | 32 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 1986 | 130 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1985 | 34 | 0.010 |
Why?
|
| Erythema | 1 | 1985 | 33 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1987 | 488 | 0.010 |
Why?
|
| Brain Diseases | 2 | 1985 | 191 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2008 | 1447 | 0.010 |
Why?
|
| Syndrome | 1 | 1986 | 450 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2006 | 550 | 0.010 |
Why?
|
| Neurocognitive Disorders | 1 | 1984 | 13 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 271 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 117 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2005 | 172 | 0.010 |
Why?
|
| Aphasia | 1 | 1984 | 17 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 1986 | 262 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2005 | 312 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 289 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1985 | 154 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2005 | 207 | 0.010 |
Why?
|
| Fibrosis | 1 | 2005 | 242 | 0.010 |
Why?
|
| Chemistry | 1 | 1983 | 54 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1983 | 72 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 2003 | 21 | 0.010 |
Why?
|
| Antilymphocyte Serum | 2 | 1980 | 69 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 724 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1749 | 0.010 |
Why?
|
| DNA Replication | 1 | 1984 | 176 | 0.010 |
Why?
|
| Liver | 2 | 2005 | 1235 | 0.010 |
Why?
|
| Defective Viruses | 1 | 2002 | 11 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1984 | 292 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1982 | 63 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 156 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1982 | 109 | 0.010 |
Why?
|
| Mycoplasmatales Infections | 1 | 1981 | 1 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1987 | 1833 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1985 | 512 | 0.010 |
Why?
|
| Sulfadiazine | 1 | 1981 | 24 | 0.010 |
Why?
|
| Calcinosis | 1 | 2003 | 231 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1982 | 153 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1982 | 126 | 0.010 |
Why?
|
| Leukocytes | 1 | 1982 | 218 | 0.010 |
Why?
|
| Electroencephalography | 2 | 2001 | 808 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 861 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1980 | 65 | 0.010 |
Why?
|
| Lymphoma | 1 | 1982 | 270 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1983 | 324 | 0.010 |
Why?
|
| Encephalitis Virus, Western Equine | 1 | 1980 | 1 | 0.010 |
Why?
|
| Deamination | 1 | 1980 | 10 | 0.010 |
Why?
|
| Eye Diseases | 1 | 1980 | 60 | 0.010 |
Why?
|
| Biological Therapy | 1 | 2000 | 47 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 979 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 1999 | 21 | 0.010 |
Why?
|
| Contraindications | 1 | 1999 | 70 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1983 | 609 | 0.010 |
Why?
|
| X-Rays | 1 | 1999 | 139 | 0.010 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 1999 | 22 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1999 | 109 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1978 | 43 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1999 | 175 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1999 | 125 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1985 | 2728 | 0.010 |
Why?
|
| Hemangiosarcoma | 1 | 1998 | 17 | 0.010 |
Why?
|
| Wound Healing | 1 | 1980 | 378 | 0.010 |
Why?
|
| France | 1 | 1998 | 54 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1998 | 55 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1179 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1998 | 85 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 1984 | 806 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2001 | 471 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1991 | 2093 | 0.010 |
Why?
|
| Nucleocapsid | 1 | 1996 | 5 | 0.010 |
Why?
|
| Transplantation, Homologous | 4 | 1979 | 1021 | 0.010 |
Why?
|
| Uterine Cervical Diseases | 1 | 1976 | 8 | 0.010 |
Why?
|
| Phytohemagglutinins | 2 | 1990 | 21 | 0.010 |
Why?
|
| Population | 1 | 1996 | 37 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 99 | 0.010 |
Why?
|
| Phototherapy | 1 | 1976 | 35 | 0.010 |
Why?
|
| Zalcitabine | 1 | 1995 | 2 | 0.010 |
Why?
|
| Didanosine | 1 | 1995 | 2 | 0.010 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 1995 | 6 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1976 | 88 | 0.010 |
Why?
|
| Federal Government | 1 | 1995 | 29 | 0.010 |
Why?
|
| London | 1 | 1975 | 17 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 1995 | 25 | 0.010 |
Why?
|
| Confidentiality | 1 | 1995 | 80 | 0.010 |
Why?
|
| Sepsis | 1 | 1999 | 371 | 0.010 |
Why?
|
| Pemphigoid Gestationis | 1 | 1975 | 1 | 0.010 |
Why?
|
| Photochemotherapy | 1 | 1976 | 101 | 0.010 |
Why?
|
| Cadaver | 3 | 1980 | 196 | 0.010 |
Why?
|
| Ureaplasma | 2 | 1987 | 5 | 0.010 |
Why?
|
| Cerebellum | 1 | 1976 | 253 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1993 | 14 | 0.010 |
Why?
|
| Hospitalization | 1 | 1999 | 942 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1993 | 171 | 0.010 |
Why?
|
| Adsorption | 1 | 1993 | 54 | 0.010 |
Why?
|
| Culture Media | 1 | 1993 | 149 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1992 | 5 | 0.010 |
Why?
|
| Iowa | 1 | 1992 | 35 | 0.010 |
Why?
|
| Personnel, Hospital | 1 | 1992 | 32 | 0.010 |
Why?
|
| Superinfection | 1 | 1992 | 3 | 0.010 |
Why?
|
| Family Health | 1 | 1992 | 159 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1992 | 198 | 0.010 |
Why?
|
| Baculoviridae | 1 | 1991 | 34 | 0.010 |
Why?
|
| HIV Antigens | 1 | 1991 | 4 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1991 | 6 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1998 | 778 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 1992 | 387 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 1991 | 24 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1976 | 766 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1990 | 23 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1991 | 89 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1991 | 129 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1990 | 32 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1991 | 110 | 0.010 |
Why?
|
| Aotus trivirgatus | 1 | 1990 | 4 | 0.010 |
Why?
|
| Codon | 1 | 1990 | 120 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 137 | 0.010 |
Why?
|
| Family | 1 | 1992 | 329 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 231 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1990 | 156 | 0.000 |
Why?
|
| Clone Cells | 1 | 1990 | 220 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 1642 | 0.000 |
Why?
|
| Transfection | 1 | 1990 | 910 | 0.000 |
Why?
|
| Anus Neoplasms | 1 | 1988 | 37 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1987 | 64 | 0.000 |
Why?
|
| Chlamydia trachomatis | 1 | 1987 | 15 | 0.000 |
Why?
|
| Saliva | 2 | 1980 | 128 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1987 | 143 | 0.000 |
Why?
|
| Monocytes | 1 | 1987 | 228 | 0.000 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1987 | 407 | 0.000 |
Why?
|
| Arabinose | 2 | 1974 | 3 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1984 | 241 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1984 | 647 | 0.000 |
Why?
|
| Autopsy | 1 | 1981 | 125 | 0.000 |
Why?
|
| Leukopenia | 1 | 1980 | 67 | 0.000 |
Why?
|
| Immune Adherence Reaction | 1 | 1979 | 4 | 0.000 |
Why?
|
| Complement Fixation Tests | 1 | 1979 | 4 | 0.000 |
Why?
|
| Azathioprine | 1 | 1979 | 124 | 0.000 |
Why?
|
| Host vs Graft Reaction | 1 | 1978 | 3 | 0.000 |
Why?
|
| Mononuclear Phagocyte System | 1 | 1976 | 2 | 0.000 |
Why?
|
| Infectious Mononucleosis | 1 | 1974 | 6 | 0.000 |
Why?
|
| Delivery, Obstetric | 1 | 1975 | 123 | 0.000 |
Why?
|
| Tissue Donors | 1 | 1978 | 541 | 0.000 |
Why?
|
| Pharynx | 1 | 1974 | 45 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1980 | 1123 | 0.000 |
Why?
|
| Adenine Nucleotides | 1 | 1973 | 63 | 0.000 |
Why?
|
| Adenine | 1 | 1973 | 90 | 0.000 |
Why?
|
| Immunosuppressive Agents | 1 | 1978 | 993 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1975 | 926 | 0.000 |
Why?
|